These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11704311)

  • 41. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
    Koukourakis MI; Tsoutsou PG; Abatzoglou I
    Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
    Rosenman J
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histologic Improvements in Irradiated Bone Through Pharmaceutical Intervention in Mandibular Distraction Osteogenesis.
    Urlaub KM; Lynn JV; Carey EG; Nelson NS; Polyatskaya Y; Donneys A; Mazzoli AC; Buchman SR
    J Oral Maxillofac Surg; 2018 Dec; 76(12):2660-2668. PubMed ID: 29883588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
    Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
    Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
    Bourhis J; De Crevoisier R; Abdulkarim B; Deutsch E; Lusinchi A; Luboinski B; Wibault P; Eschwege F
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1105-8. PubMed ID: 10725619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).
    Bradley JD; Scott CB; Paris KJ; Demas WF; Machtay M; Komaki R; Movsas B; Rubin P; Sause WT
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1173-9. PubMed ID: 11955727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma.
    Giuliani ME; Lindsay PE; Kwan JY; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
    Clin Lung Cancer; 2015 May; 16(3):216-20. PubMed ID: 25532963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
    Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
    Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
    Katsanos KH; Briasoulis E; Tsekeris P; Batistatou A; Bai M; Tolis C; Capizzello A; Panelos I; Karavasilis V; Christodoulou D; Tsianos EV
    J Exp Clin Cancer Res; 2010 Jun; 29(1):68. PubMed ID: 20537164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosimetric factors used for thoracic X-ray radiotherapy are not predictive of the occurrence of radiation pneumonitis after carbon-ion radiotherapy.
    Koto M; Tsujii H; Yamamoto N; Nishimura H; Yamada S; Miyamoto T
    Tohoku J Exp Med; 2007 Oct; 213(2):149-56. PubMed ID: 17917408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
    Sarna L; Swann S; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Byhardt R; Wasserman T; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1378-84. PubMed ID: 18501528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
    Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
    Devine A; Marignol L
    Anticancer Res; 2016 Jan; 36(1):5-12. PubMed ID: 26722022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.